Related Experiment Video

Updated: Jun 18, 2026

Fluorescence-Based Quantification of Mitochondrial Membrane Potential and Superoxide Levels Using Live Imaging in HeLa Cells
06:57

Fluorescence-Based Quantification of Mitochondrial Membrane Potential and Superoxide Levels Using Live Imaging in HeLa Cells

Published on: May 12, 2023

Deficiency of LIMA1 accelerates bladder cancer progression by disrupting PINK1/Parkin-mediated mitophagy

Shuchen Zhao1,2, Shuang Xu1,2, Kai Cao1,2

  • 1Department of Urology, Changzhou Medical Center, Changzhou Wujin People's Hospital, Nanjing Medical University, Changzhou, 213003, China.

Cell Death Discovery
|June 16, 2026
PubMed

Insights

The cytoskeletal protein LIMA1 suppresses bladder cancer (BLCA) by regulating mitochondrial autophagy via the PINK1-Parkin pathway. Its deficiency promotes tumor growth and poor prognosis, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The role of LIM domain and actin-binding protein 1 (LIMA1) as a tumor suppressor in bladder cancer (BLCA) is not well-defined.
  • Cytoskeletal proteins can influence cancer progression and serve as potential therapeutic targets.

Purpose of the Study:

  • To investigate the role and mechanism of LIMA1 in bladder cancer (BLCA).
  • To explore the potential of targeting the LIMA1 pathway for BLCA treatment.

Main Methods:

  • Clinical analysis of LIMA1 expression in BLCA tissues and serum.
  • Functional studies involving LIMA1 knockout in a mouse xenograft model.
  • Database prediction and molecular docking to identify LIMA1 interacting partners.
  • Investigation of the PINK1-Parkin pathway and mitochondrial autophagy.

Main Results:

  • LIMA1 is significantly downregulated in BLCA tissues and serum, correlating with advanced stage, grade, and recurrence risk.
  • LIMA1 deficiency promotes tumor cell proliferation, migration, invasion, and increases tumor volume.
  • LIMA1 directly binds to PINK1, enhancing mitochondrial autophagy via the PINK1-Parkin pathway.
  • Uric acid A reverses malignant phenotypes associated with LIMA1 deficiency.

Conclusions:

  • LIMA1 acts as a tumor suppressor in BLCA by inhibiting progression through the LIMA1/PINK1/mitochondrial autophagy pathway.
  • LIMA1 downregulation is linked to poor prognosis in BLCA patients.
  • Targeting the LIMA1/PINK1/mitochondrial autophagy pathway offers a novel therapeutic strategy for BLCA.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...